Status:
TERMINATED
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
Lead Sponsor:
Wei Hao
Conditions:
Methamphetamine Dependence
Eligibility:
All Genders
19-65 years
Phase:
PHASE4
Brief Summary
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharm...
Detailed Description
Methods:A Multiple-Center, Randomized, Double-Blind.
Eligibility Criteria
Inclusion
- Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.
- Must sign a Information consent form.
- Required to provide detailed address and phone number
Exclusion
- Serious organic disease.
- Suicide ideation or hurt others.
- Taking antipsychotic within two weeks before.
- drug allergy to Risperidone or Aripiprazole.
- pregnancy and breastfeeding women.
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01813656
Start Date
September 1 2012
End Date
February 1 2014
Last Update
February 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Xiangya Hospital of Central University
Changsha, Hunan, China, 410011